Literature DB >> 23331375

Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study.

Yann Neuzillet1, Michel Soulie, Stéphane Larre, Morgan Roupret, Guillaume Defortescu, Thibaut Murez, Géraldine Pignot, Aurélien Descazeaud, Jean-Jacques Patard, Pierre Bigot, Laurent Salomon, Pierre Colin, Jérôme Rigaud, Cyrille Bastide, Xavier Durand, Antoine Valeri, François Kleinclauss, Franck Bruyere, Christian Pfister.   

Abstract

OBJECTIVE: To compare the prognoses associated with positive surgical margins (PSMs) according to their urethral, ureteric and/or soft tissue locations in patients with pN0 M0 bladder cancer who have not undergone neoadjuvant chemotherapy. PATIENTS AND METHODS: A retrospective, case-control study was conducted between 1991 and 2011 using data from 17 academic centres in France. A total of 154 patients (cases) with PSMs met the eligibility criteria and were matched according to centre, pT stage, gender, age and urinary diversion method with a population-based sample of 154 patients (controls) from 3651 patients who had undergone cystectomies. The median follow-up period was 23.9 months. Multivariable Cox regression analysis was used to test the effects of PSMs on local recurrence (LR)-free survival, metastatic recurrence (MR)-free survival and cancer-specific survival (CSS).
RESULTS: The 5-year LR-free survival and CSS rates of patients with urethral and soft tissue PSMs were lower than those in the control group. A significant decrease in CSS was associated with soft tissue PSMs (P = 0.003, odds ratio = 0.425, 95% confidence interval 0.283-0.647). The prognosis was not affected in cases of ureteric PSMs.
CONCLUSIONS: Soft tissue PSMs were associated with poor CSS rates in patients with pN0 M0 bladder cancer. A correlation between urethrectomy and a reduction of the risk of LR in a urethral PSM setting was observed.
© 2013 BJU International.

Entities:  

Mesh:

Year:  2013        PMID: 23331375     DOI: 10.1111/j.1464-410X.2012.11664.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  E Compérat; J R Srigley; F Brimo; B Delahunt; M Koch; A Lopez-Beltran; V Reuter; H Samaratunga; J H Shanks; T Tsuzuki; T van der Kwast; M Varma; F Webster; D Grignon
Journal:  Virchows Arch       Date:  2020-01-08       Impact factor: 4.064

Review 2.  Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.

Authors:  Eva Compérat; André Oszwald; Gabriel Wasinger; Donna E Hansel; Rodolfo Montironi; Theodorus van der Kwast; Johannes A Witjes; Mahul B Amin
Journal:  World J Urol       Date:  2021-09-23       Impact factor: 3.661

3.  The clinical significance of intra-operative ureteral frozen section analysis at radical cystectomy for urothelial carcinoma of the bladder.

Authors:  Hyung Suk Kim; Kyung Chul Moon; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  World J Urol       Date:  2014-05-14       Impact factor: 4.226

4.  Utility of Routine Intraoperative Ureteral Frozen Section Analysis at Radical Cystectomy: Outcomes from a Regional Australian Center.

Authors:  Joanne Tang; Weranja Ranasinghe; Janice Cheng; Sabiena Van Es; Mike Monsour; Richard Cetti; Robert Jensen; Steve Brough
Journal:  Curr Urol       Date:  2019-03-08

5.  Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.

Authors:  Francesco Claps; Maaike W van de Kamp; Roman Mayr; Peter J Bostrom; Joost L Boormans; Markus Eckstein; Laura S Mertens; Egbert R Boevé; Yann Neuzillet; Maximilian Burger; Damien Pouessel; Carlo Trombetta; Bernd Wullich; Theo H van der Kwast; Arndt Hartmann; Yves Allory; Yair Lotan; Shahrokh F Shariat; Tahlita C M Zuiverloon; M Carmen Mir; Bas W G van Rhijn
Journal:  World J Urol       Date:  2021-07-01       Impact factor: 4.226

Review 6.  Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?

Authors:  Paul Sargos; Brian C Baumann; Libni J Eapen; Amit Bahl; Vedang Murthy; Guilhem Roubaud; Mathieu Orré; Jason A Efstathiou; Shahrokh Shariat; Stephane Larré; Pierre Richaud; John P Christodouleas
Journal:  Transl Androl Urol       Date:  2016-10

Review 7.  Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.

Authors:  Andrea Mari; Riccardo Campi; Riccardo Tellini; Giorgio Gandaglia; Simone Albisinni; Mohammad Abufaraj; Georgios Hatzichristodoulou; Francesco Montorsi; Roland van Velthoven; Marco Carini; Andrea Minervini; Shahrokh F Shariat
Journal:  World J Urol       Date:  2017-11-16       Impact factor: 4.226

8.  Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.

Authors:  Mathieu Orré; Igor Latorzeff; Aude Fléchon; Guilhem Roubaud; Véronique Brouste; Richard Gaston; Thierry Piéchaud; Pierre Richaud; Olivier Chapet; Paul Sargos
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

Review 9.  Raman Spectroscopy: A Personalized Decision-Making Tool on Clinicians' Hands for In Situ Cancer Diagnosis and Surgery Guidance.

Authors:  Maria Anthi Kouri; Ellas Spyratou; Maria Karnachoriti; Dimitris Kalatzis; Nikolaos Danias; Nikolaos Arkadopoulos; Ioannis Seimenis; Yannis S Raptis; Athanassios G Kontos; Efstathios P Efstathopoulos
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

10.  Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Authors:  Makito Miyake; Shunta Hori; Sayuri Ohnishi; Michihiro Toritsuka; Tomomi Fujii; Takuto Shimizu; Takuya Owari; Yosuke Morizawa; Daisuke Gotoh; Yoshitaka Itami; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Cancer Sci       Date:  2019-08-19       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.